Archive: November 2022

Ongoing Progress in BRAF-Mutated Non–Small Cell Lung Cancer

Abstract: Activating BRAF mutations are detected in 1.5% to 4.5% of patients with non–small cell lung cancer (NSCLC). These mutations involve the mitogen-activated protein kinase/extracellular signal-regulated […]

The Role of Cytoreductive Surgery and Intraperitoneal Chemotherapy in Gastric Cancer

Abstract: Gastric cancer (GC) with peritoneal carcinomatosis (PC) progresses rapidly and has historically dismal survival rates. Given the aggressive tumor biology and poor survival outcomes of […]

The Use of AI to Identify Predictive, Pathology-Based Biomarkers in Men With Prostate Cancer

H&O  How is artificial intelligence (AI) defined in the context of cancer biomarkers, including predictive biomarkers?  DS  AI is a very general term, of course, that […]

Advances in Immune Checkpoint Inhibition for Patients With Lung Cancer

H&O  What are the newest indications for checkpoint inhibitors in lung cancer? HB  The newest indication in the neoadjuvant setting is the use of nivolumab (Opdivo, […]

Key Points From the SHINE Trial in Mantle Cell Lymphoma

H&O  Could you provide some background on mantle cell lymphoma? JT  Mantle cell lymphoma is an uncommon type of lymphoma. It represents approximately 6% of non-Hodgkin […]

Letter From the Editor: Computational Faith

I have always had great reverence for our colleagues in biostatistics. Whether my reverence derives from the limitations of my own statistical training or from the […]

Serving on the FDA Oncologic Drugs Advisory Committee

H&O  What is the role of the Oncologic Drugs Advisory Committee (ODAC) of the US Food and Drug Administration (FDA)?  PH  ODAC is one of several […]

November 2022

Back to Archive